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Is thalidomide a good option for patients with 
refractory Crohn’s disease? 
 
Gerhard Rogler1  
 
1Department of Gastroenterology & Hepatology, University Hospital of Zürich, Zürich, 
Switzerland 
  
The history of thalidomide is inevitably connected with its serious teratogenicity. In recent 
years, however, its beneficial biological activities lead to a renaissance of its use 1. Thalidomide 
has an inhibitory activity against tumor necrosis factor-α (TNF-α) known to play an important 
pathophysiological role in Crohn's disease (CD). In 1998 the FDA re-approved thalidomide for 
erythema nodosum leprosum (ENL) and recently for multiple myeloma 2.  
As thalidomide targets TNF and there are refractory CD patients in need for additional 
treatments thalidomide has been introduced in CD treatment and several reports have been 
published recently3-6. Gerich and colleagues report on the outcome of 37 patients with 
refractory CD from a  single-centre, retrospective, observational cohort from the Cedars-Sinai 
Medical Center7. The patients had moderate-to-severe CD that was refractory to available 
standard therapies7. Thalidomide was administrated at a starting dose of 50–100mg at night 
and increased to a maximum of 200mg/day if necessary7. A clinical response was observed in 
54% and a clinical remission in 19% of patients. 
Given the risk of teratogenicity and the high rates of side effects these numbers are somewhat 
disappointing. They indicate that in each case a careful risk/benefit analysis will be necessary.  
In this real life open label setting remission rates are surprisingly lower as compared to a recent 
RCT in pediatric patients in whom a remission rate of 46% (12% for placebo) was reported8. 
During a median treatment time of 4.4 months adverse events occurred in 68% of patients and 
38% experienced neuropathy7. The latter is quite a concerning number given the relatively 
short treatment time. This leads to an important consideration: Long term treatment at least in 
adult patients is not possible due to side effects9. So the question arises what long term benefit 
the treated patients can expect. Thalidomide cannot be used as maintenance therapy based on 
recent reports3-6 and the present one9. So is this a desirable perspective for patients that have 
chronic active CD and would require a maintenance treatment? Will patients want a treatment 
with a remission rate of 19% without a perspective of long term treatment? This remains 
questionable.    
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